CD274 and neoplasm: Neoantigen vaccines stimulate robust T cell responses by presenting tumor-specific antigens, while ICIs inhibit immune checkpoint pathways (e.g., PD-1/PD-L1), preventing T cell exhaustion and enhancing antitumor activity.